Prevention of Venous Thromboembolism in Total Knee and Hip Replacement

David Warwick, MD, FRCS, FRCS(Orth)

Case presentation: A 69-year-old woman had a cemented hip replacement 15 years previously, which initially fared well but then gradually failed because of aseptic loosening. She developed pain in her hip and was scheduled for a revision total hip replacement. A formal venous thromboembolism (VTE) risk assessment was undertaken before surgery according to the Hospital’s policy for all orthopedic admissions. The risk assessment identified 2 conflicting issues. First, the patient had a particularly high risk of VTE, having had an above-knee deep vein thrombosis after her primary hip replacement and now required a major surgery, namely a revision hip arthroplasty. Second, she had a greater than usual risk of bleeding after surgery because of her obesity and the need for a large soft-tissue exposure, long-term aspirin, and supplementary bone graft from her iliac crest. The surgeon was faced with a common orthopedic problem, providing effective VTE prophylaxis without causing an equally important problem of surgical bleeding.

Introduction

Hip and knee replacement operations are now commonly performed, around 1 million annually in the United States and about the same number in Europe. These procedures are among the most successful and life-changing interventions available.

However, the release of thromboplastins from dissected soft tissue and especially reamed bone, as well as venous stasis both during surgery and during relative postoperative immobility, provoke a high rate of thromboembolism.

Several measures reduce the risk of VTE, but orthopedic surgeons are intuitively and properly concerned about the potential hemorrhagic side effect of pharmacological prophylaxis, which is associated with prolonged recovery, wound failure, and even periprosthetic infection.1 After all, following the Hippocratic principle of primum non nocere, the most thrombosceptic surgeons have even argued that whereas a thrombosis is an act of God, bleeding is caused by a surgeon. Who is to say that a symptomatic leg thrombosis is any more important than a symptomatic wound bleed or that a fatal embolism is more important than a fatal cerebral or retroperitoneal bleed? Studies of all-cause mortality in orthopedics have shown no clear change in mortality rates with or without prophylaxis.2 The symptomatic nonfatal VTE rate of around 3% to 4% without prophylaxis may be no different from the increased rate of bleeding induced by pharmacological prophylaxis. A balanced approach, individualized for each patient, is therefore required to secure the safest outcome.

Available Options and Evidence

There are many consensus statements and meta-analyses, a few of which we cite.3–10

General

It is likely that early mobilization, careful surgical technique, and adequate rehydration will all reduce the risk of VTE after joint arthroplasty.

Mechanical

Graduated compression stockings are of some benefit but must be well fitted. Mechanical foot or calf compressors are effective as well in total hip arthroplasty and total knee arthroplasty, although probably not quite as effective as the best pharmacological methods. They have the drawbacks of impracticality and lack of compliance, espe-
though warfarin is now generally re-widely used in North America, al-

Older Oral Agents

Injectable Agents

New Oral Agents

The past 3 years have seen the advent of new oral agents, anti Xa or direct thrombin inhibitors. The anti Xa agent rivaroxaban is available in the United States for VTE prophylaxis in total hip

rivaroxaban is available in the United

of new oral agents, anti Xa or direct

the underlying theme of this article.

The various pharmacological options are summarized in Table 2. There may be discrepancies between the official manufacturer’s product information, based on clinical trial programs, and the pragmatic and considered protocols advised by professional guidelines. These discrepancies are an underling theme of this article.

When to Start, When to Finish

The thrombotic process starts as soon as the arthroplasty starts, and so thromboprophylaxis must be started as close to surgery as possible.13 Pharmacological prophylaxis can be started before surgery, but if too close there will be a risk of bleeding; if too far before surgery, the drug effect will have decayed before the thrombotic process commences. Preoperative administration is also compromised because an unexpected delay in surgery or an earlier than expected procedure will exacerbate these problems. Postoperative administration is therefore more reliable with regard to a precise time for com-

Table 1. Drawbacks of Warfarin and Aspirin, Advantages of New Oral Agents

Drawbacks of Warfarin

Advantages of new oral agents

Disadvantages of new oral agents

only weak antithrombotic effect so limited efficacy
Evidence base controversial
GI bleeding, wound bleeding
Controversial professional support. Not recommended by NICE or ACCP, but recommended by first AAOS guidelines. Caution advised in 2011 AAOS guidelines.
Not licensed for thromboprophylaxis
At least as effective as enoxaparin
Comparable bleeding profile
No drug interactions
No monitoring
Can be used for out-of-hospital prophylaxis
Less prone to HIT than LMWH
Only recently available, no long-term experience (vs LMWH)

LMWH indicates low–molecular-weight heparin; NICE, National Institute for Health and Clinical Excellence; ACCP, American College of Chest Physicians; AAOS, American Academy of Orthopaedic Surgeons; and HIT, heparin induced thrombocytopenia.

Table 1. Drawbacks of Warfarin and Aspirin, Advantages of New Oral Agents

Drawbacks of Warfarin

Needs regular monitoring, which is expensive and time consuming
If started too close to surgery or at too high a dose, there will be a risk of bleeding
If started judiciously, later and at a lower dose, there will be an interval of several days during which the patient will be unprotected during his or her most thrombogenic phase
Interaction with many drugs and alcohol
Probably not as effective as LMWH

Advantages of new oral agents

Only weak antithrombotic effect so limited efficacy
Evidence base controversial
GI bleeding, wound bleeding
Controversial professional support. Not recommended by NICE or ACCP, but recommended by first AAOS guidelines. Caution advised in 2011 AAOS guidelines.
Not licensed for thromboprophylaxis
At least as effective as enoxaparin
Comparable bleeding profile
No drug interactions
No monitoring
Can be used for out-of-hospital prophylaxis
Less prone to HIT than LMWH
Disadvantages of new oral agents

Poor reversibility
Caution in certain groups (eg, renal impairment)

Drawbacks of Aspirin

Older Oral Agents

Aspirin and warfarin (Coumadin) are widely used in North America, although warfarin is now generally regarded as obsolete in Europe. Aspirin is controversial (Table 1).

Neuraxial Anesthesia

Neuraxial anesthesia reduces VTE in arthroplasty and also reduces overall mortality.9 However, the anesthetist

When to Start, When to Finish

The thrombotic process starts as soon as the arthroplasty starts, and so thromboprophylaxis must be started as close to surgery as possible.13 Pharmacological prophylaxis can be started before surgery, but if too close there will be a risk of bleeding; if too far before surgery, the drug effect will have decayed before the thrombotic process commences. Preoperative administration is also compromised because an unexpected delay in surgery or an earlier than expected procedure will exacerbate these problems. Postoperative administration is therefore more reliable with regard to a precise time for com-

rivaroxaban is available in the United

Neuraxial Anesthesia

Neuraxial anesthesia reduces VTE in arthroplasty and also reduces overall mortality.9 However, the anesthetist

practical administration for a longer duration, especially after hospital discharge. They have the further advantage over existing oral agents relative to efficacy (aspirin), as well as avoidance of monitoring and potential drug interactions (warfarin). They are likely to change the way that prophylaxis is administered in orthopedic patients, in particular meeting the previously unmet need for pragmatic out-of-hospital prophylaxis.

The various pharmacological options are summarized in Table 2. There may be discrepancies between the official manufacturer’s product information, based on clinical trial programs, and the pragmatic and considered protocols advised by professional guidelines. These discrepancies are an underlying theme of this article.

When to Start, When to Finish

The thrombotic process starts as soon as the arthroplasty starts, and so thromboprophylaxis must be started as close to surgery as possible.13 Pharmacological prophylaxis can be started before surgery, but if too close there will be a risk of bleeding; if too far before surgery, the drug effect will have decayed before the thrombotic process commences. Preoperative administration is also compromised because an unexpected delay in surgery or an earlier than expected procedure will exacerbate these problems. Postoperative administration is therefore more reliable with regard to a precise time for com-
mencement, but there is still a balance between giving the drug too soon (and risking bleeding) and too late (and risking thrombosis) (Figure 1).

The duration of risk of VTE must also be considered. The risk after knee replacement is around 2 weeks and for hip replacement 4 to 6 weeks. The risk may be longer in some individuals with extra risk factors. Prophylaxis should be continued until the risk has diminished (Figure 2). Because joint replacement patients only remain in hospital for a few days, prophylaxis must be extended beyond hospital discharge. This raises practical issues which can be readily addressed with an effective oral agent. Injectable agents and mechanical devices are less practical after hospital discharge.

Guidelines

Prophylaxis in the United States and Europe is now usually determined by hospital policy informed by guidelines. Guidelines distill the evidence and provide a reasoned and balanced practical summary for the surgeon. Regular application of guidelines should help facilitate the implementation of prophylaxis.

Despite a similar evidence base, guidelines vary. The American Academy of Orthopaedic Surgeons prefers pulmonary embolism as an end point and, with a paucity of studies providing this end point, cannot make firm recommendations on the basis of comparative studies. The first version in 2007 tended toward aspirin and warfarin postoperatively; the latest 2011 iteration recommends the avoidance of aspirin before surgery and recommends postoperative pharmacological methods or mechanical methods for hip and knee arthroplasty. Those with a higher risk of thrombosis should have both; those with a higher risk of bleeding should have mechanical methods. Other guidelines, such as those of the American College of Chest Physicians and the International Consensus Statement are based on a venographic surrogate; this approach supports much firmer recommendations because there are a large number of studies with adequate sample size and significant differences in proportions between randomized groups. New iterations of each are due in 2012. The United Kingdom National Institute for Clinical Excellence guidelines are a little less prescriptive, allowing some flexibility in timing of administration and combinations of mechanical and chemical methods.

A Balanced Approach

It is generally held that hip and knee replacement have a risk of VTE high

Table 2. Pharmaceutical Options in Total Hip Arthroplasty and Total Knee Arthroplasty

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Brand Name</th>
<th>Class</th>
<th>Manufacturer</th>
<th>Route</th>
<th>Timing</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enoxaparin</td>
<td>Lovenox</td>
<td>LMWH</td>
<td>Sanofi-Aventis</td>
<td>sc</td>
<td>Postop &gt;12 hours</td>
<td>Twice daily</td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>Clexane</td>
<td>LMWH</td>
<td>Sanofi-Aventis</td>
<td>sc</td>
<td>Preop 12 hours</td>
<td>Once daily</td>
</tr>
<tr>
<td>Dalteparin</td>
<td>Fragmin</td>
<td>LMWH</td>
<td>Pfizer Inc/Eisai Inc</td>
<td>sc</td>
<td>Preop</td>
<td>Once daily</td>
</tr>
<tr>
<td>Tinzaparin</td>
<td>Innohep</td>
<td>LMWH</td>
<td>Leo Pharmaceuticals</td>
<td>sc</td>
<td>Preop</td>
<td>Once daily</td>
</tr>
<tr>
<td>Fondaparinux</td>
<td>Anxtia</td>
<td>Pentasaccharide</td>
<td>GlaxoSmithKline</td>
<td>sc</td>
<td>&gt;6–8 hours postop</td>
<td>Once daily</td>
</tr>
<tr>
<td>Warfarin</td>
<td>Coumadin</td>
<td>Ant-Xa Vitamin K antagonist</td>
<td>Bristol-Myers-Squibb/Pfizer</td>
<td>po</td>
<td>variable</td>
<td>Once daily</td>
</tr>
<tr>
<td>Apixaban</td>
<td>Eliquis</td>
<td>Anti-Xa</td>
<td>Bristol-Myers-Squibb/Pfizer</td>
<td>po</td>
<td>12–24 hours postop</td>
<td>Twice daily</td>
</tr>
<tr>
<td>Rivaroxaban</td>
<td>Xarelto</td>
<td>Anti-Xa</td>
<td>Bayer</td>
<td>po</td>
<td>Postop &gt;8 hours</td>
<td>Once daily</td>
</tr>
<tr>
<td>Dabigatran</td>
<td>Pradaxa</td>
<td>Direct thrombin inhibitor</td>
<td>Boeringher Ingelheim</td>
<td>po</td>
<td>Postop 1–4 hours</td>
<td>Once daily</td>
</tr>
</tbody>
</table>

This is a guide only. Any drug on this table should only be prescribed after confirmation by the prescribing physician of all data on dose, duration, indications, and contra-indications. For duration of administration, refer to both professional guidelines and manufacturer’s product information.

LMWH indicates low–molecular-weight heparin; sc, by injection; postop, after surgery; preop, before surgery; and po, by mouth.
Figure 2. Discrepancy between duration of prophylaxis and onset of symptomatic VTE. VTE indicates venous thromboembolism. Reproduced with permission and copyright © of the British Editorial Society of Bone and Joint Surgery. 14

Disclosures
Dr Warwick has received honoraria and traveling expenses from Boehringer Ingelheim (manufacturers of Dabigatran, a direct thrombin inhibitor) for 2 lectures in 2011 and 1 in 2010. The author received traveling expenses for his contribution to the International Consensus Statement Editorial Board in 2011.

References
8. Nicolaides AN, Breddin HK, Carpenter P, Coccheri S, Conard J, De Stefano V, Elkoofy...


Prevention of Venous Thromboembolism in Total Knee and Hip Replacement
David Warwick

Circulation. 2012;125:2151-2155
doi: 10.1161/CIRCULATIONAHA.111.055731
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/125/17/2151

An erratum has been published regarding this article. Please see the attached page for:
/content/126/10/e159.full.pdf

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/
In the article by Warwick, “Prevention of Venous Thromboembolism in Total Knee and Hip Replacement,” which was published in the May 1, 2012 issue of the journal (Circulation. 2012;125:2151–2155), the following errors occurred:

In the legend to Table 1, the abbreviation “NICE” is expanded to “National Institute for Clinical Excellence.” The correct expansion of “NICE” is National Institute for Health and Clinical Excellence.

In Table 2, “GlaxoSmithKlein” should read “GlaxoSmithKline.” “Bristol Myer Squibb/Pfizer” should read “Bristol-Myers Squibb/Pfizer.”

Table 2, the brand name provided for the generic “Rivaroxaban” should be “Xarelto,” not “Pradaxa.”

These errors have been corrected in the current online version of the article. The authors regret the errors.